Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, is pleased to announce the filing of two trademark names for the commercial use of its skin cancer formulation, currently identified as Sol.
The Company filed UK trademark applications, to register the signs ACTINOMOD and ACTINODERM on 22 and 21 September 2021 respectively. The applications were given application numbers UK00003699147 and UK00003698302 respectively. The applications will now be examined by the UK trade marks office (UKIPO).
These filings are in line with the ongoing progression of Incanthera’s commercialisation goals for its innovative skin cancer technology formulation.
The Company continues to positively progress discussions with two prioritised global companies for the potential license of its formulation for the treatment of actinic keratosis and prevention of skin cancer.
Tim McCarthy, Chairman said:
“As our licencing discussions progress, the filing of these two trademark names will allow us to look at various branding and marketing opportunities in readiness for next steps.
We continue to make good progress in discussions with our two prioritised partners.”
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).
The directors of the Company take responsibility for this announcement.
For further information, please contact:
Tim McCarthy, Chairman
+44 (0) 7831 675747
Simon Ward, Chief Executive Officer
+44 (0) 7747 625506
Suzanne Brocks, Head of Communications
+44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis
+44 (0) 20 7213 0880
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob Pountney
+44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.
The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics (“ICT”) at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.
Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com